1. Home
  2. CII vs ABCL Comparison

CII vs ABCL Comparison

Compare CII & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Capital and Income Fund Inc.

CII

Blackrock Capital and Income Fund Inc.

HOLD

Current Price

$21.83

Market Cap

916.6M

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.44

Market Cap

910.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CII
ABCL
Founded
2004
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
916.6M
910.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CII
ABCL
Price
$21.83
$3.44
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.75
AVG Volume (30 Days)
92.0K
3.5M
Earning Date
01-01-0001
05-26-2026
Dividend Yield
6.17%
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$15.20
$1.89
52 Week High
$26.17
$6.52

Technical Indicators

Market Signals
Indicator
CII
ABCL
Relative Strength Index (RSI) 33.91 48.73
Support Level $21.53 $3.37
Resistance Level $22.30 $3.57
Average True Range (ATR) 0.27 0.22
MACD -0.02 0.06
Stochastic Oscillator 2.15 54.02

Price Performance

Historical Comparison
CII
ABCL

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: